Pathway Genomics has launched its BreastTrue High Risk Panel, a next-generation sequencing-based assay with deletion/duplication analysis to detect mutations in seven high-risk cancer susceptibility genes — BRCA1, BRCA2, PALB2, CDH1, PTEN, STK11, and TP53. The test can analyze DNA from either blood or saliva. In addition, it has now added the option for customers that test negative using its BRCATrue and BRCATrue Ashkenazi Jewish panels to reflex to the BreastTrue panel.
New Products: Pathway Genomics' BreastTrue Panel
Sep 10, 2014